Cargando…

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities

SIMPLE SUMMARY: Estimating postoperative survival in patients undergoing surgery for metastatic bone disease of the extremities is important in order to choose an implant that will outlive the patient. The present study suggests that plasma IL-6, reflecting the inflammatory state of the patient, is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sørensen, Michala Skovlund, Colding-Rasmussen, Thomas, Horstmann, Peter Frederik, Hindsø, Klaus, Dehlendorff, Christian, Johansen, Julia Sidenius, Petersen, Michael Mørk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201042/ https://www.ncbi.nlm.nih.gov/pubmed/34200156 http://dx.doi.org/10.3390/cancers13112833

Ejemplares similares

Use of endoprostheses for proximal femur metastases results in a rapid rehabilitation and low risk of implant failure. A prospective population-based study
por: Sørensen, Michala Skovlund, et al.
Publicado: (2019)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Extent of Surgery Does Not Influence 30-Day Mortality in Surgery for Metastatic Bone Disease: An Observational Study of a Historical Cohort
por: Sørensen, Michala Skovlund, et al.
Publicado: (2016)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2021)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Surgical Treatment of Metastatic Bone Disease—When Decisions at End-of-Life Really Makes the Difference
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

Quantitative measurements of adaptive bone remodeling around the cemented Zimmer® segmental stem after tumor resection arthroplasty using dual-energy x-ray absorptiometry
por: Enciso Holm, Christina, et al.
Publicado: (2021)

Clinical outcome after surgery on schwannomas in the extremities
por: Granlund, Andreas Saine, et al.
Publicado: (2021)

Antibiotic Elution Characteristics and Pharmacokinetics of Gentamicin and Vancomycin from a Mineral Antibiotic Carrier: An in vivo Evaluation of 32 Clinical Cases
por: Colding-Rasmussen, Thomas, et al.
Publicado: (2018)

Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases
por: Peltonen, Reetta, et al.
Publicado: (2020)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall—study protocol for a randomized controlled trial
por: Yilmaz, Müjgan, et al.
Publicado: (2022)

Evaluation of tumor-prostheses over time: Complications, functional outcome, and comparative statistical analysis after resection and reconstruction in orthopedic oncologic conditions in the lower extremities
por: Holm, Christina Enciso, et al.
Publicado: (2022)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
por: Knudsen, Lene Surland, et al.
Publicado: (2009)

Dislocation rate after hip arthroplasty due to metastatic bone disease: a retrospective cohort study evaluating the postoperative dislocation risk across different articulating solutions
por: ILJAZI, Afrim, et al.
Publicado: (2023)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

Fully constrained acetabular liner vs. dual mobility hip joint in the surgical treatment of metastatic bone disease of the hip: study protocol for a randomized, open-label, two-arm, non-inferiority trial evaluating the post-operative hip dislocation rate
por: Iljazi, Afrim, et al.
Publicado: (2023)

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
por: Shao, Rong, et al.
Publicado: (2009)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Response from authors (Sorensen et al.)
por: Sørensen, Michala Skovlund
Publicado: (2020)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
por: Gevezova, Maria, et al.
Publicado: (2023)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality – a cohort study
por: Sørensen, Allan Klitgaard, et al.
Publicado: (2015)

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis
por: Shao, Rong
Publicado: (2013)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qopvb99hvq444hlbh0u6a1g9rr